Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when PRAX files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsRed Flags Detected
- Primary Endpoint Miss (new) — Lead drug candidate failed to meet primary success measure in pivotal Phase 2/3 trial
- Enrollment Pause (new) — Company halted second trial to reassess program, signaling uncertainty about path forward
Praxis halts vormatrigine trial enrollment after Phase 2/3 study misses primary endpoint
Filed June 1, 2026 · Period ending June 1, 2026 · ~1 min read
Key Changes
-
high
POWER1 Phase 2/3 trial in focal onset seizures failed primary endpoint, though secondary 50% response rate was met and higher doses showed more seizure reduction in second half of study
Item 8.01 verify on EDGAR → -
high
Company paused enrollment in POWER2 trial to reassess vormatrigine program and determine potential modifications to clinical strategy
Item 8.01 verify on EDGAR → -
medium
Drug was generally well-tolerated with under 10% discontinuations due to adverse events; approximately 90% of vormatrigine patients transitioned to open-label extension study
Item 8.01 verify on EDGAR →
Summary
Praxis disclosed that vormatrigine, its lead drug candidate for focal onset seizures, failed to meet the primary endpoint in the POWER1 Phase 2/3 trial in highly refractory patients. While the secondary 50% response rate was achieved and higher 30mg doses showed more pronounced seizure reduction in the study's second half, the primary endpoint miss represents a significant setback.
The company has paused enrollment in its second Phase 2/3 trial, POWER2, to reassess the program and determine potential modifications to its clinical strategy. For investors, this creates substantial uncertainty about vormatrigine's regulatory path and commercial viability. The primary endpoint failure may require additional trials or protocol changes before seeking approval.
However, the favorable safety profile—with under 10% adverse-event-related discontinuations—and the fact that 90% of trial participants continued into the open-label extension suggest patients and physicians see potential benefit. The company's next steps in modifying the development program will be critical to determining whether vormatrigine remains a viable asset.
Section-by-Section Diff
Event · Item 8.01 — Other Events
Item 8.01 — Other Events filed; see Key Changes for terms.
Added in current filing · verify on EDGAR →
The Company is pausing enrollment in the POWER2 study to reassess the vormatrigine program and determine potential modifications.
The company has halted enrollment in its second Phase 2/3 trial (POWER2) to reassess the vormatrigine development program and consider modifications. This pause indicates the company is re-evaluating its clinical strategy following the POWER1 primary endpoint miss.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Jul 3, 2026 · How we verify